AAP recommendations expand second-season RSV protection criteria for children ages 8 to 19 months, plus infant COVID-19 ...

Targeting key cellular proteins may provide new opportunities to diagnose, prevent, and treat pulmonary arterial hypertension ...

IDSA recommendations emphasize the safety and importance of COVID-19, influenza, and RSV vaccines immunocompromised patients.

GE HealthCare issued updated use instructions for certain patient monitoring devices, according to an FDA alert.

Updated formulas from Pfizer, Moderna, and Novavax target the circulating XFG variant for older adults and high-risk ...

Inhalation Solution would become the first inhaled option designed to treat idiopathic pulmonary fibrosis (IPF).

FDA will review Enflonsia's ability to protect high-risk children under 2 years of age during their second RSV season.

A clinical trial will evaluate a weekly dry powder nasal spray's ability to boost natural defenses and prevent asthma infections.

The latest round of products brings the total number of FDA-authorized flavored nicotine pouches to 43 overall.

The ERS is urging European countries to adopt "tobacco endgame" policies to permanently reduce tobacco use and end the ...

CooperSurgical issued a letter recommending certain neonatal nasal CPAP devices be removed from where they are used or sold.

Mercyhurst University will reinstate its respiratory therapy degree program through a new partnership with the UPMC.